ASCO Journal Club   

Is the data sufficient to change your practice?

Does cumulative exposure to BTKi increase potential risk of cardiac toxicity?

Should pirtobrutinib be viewed as a bridge to CAR-T or transplant or a destination therapy?

How do you predict which patients may be in a high risk group and less likely to benefit from a second BTKi?

Is there a specific Ki67 percentage? P53-negativity? 

Are you using ctDNA blood tests for targetable mutations at the time of diagnosis, at the time of disease progression, or not at all?